Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma
NCT00665470 is a phase 2 interventional trial sponsored by National Cancer Institute (NCI). As of 21 Nov 2026, it is completed. It studies Aldesleukin in Metastatic Melanoma and Skin Cancer. The registry lists an enrollment of 10 participants at 1 site in 1 country. The registry lists a start date of 30 Apr 2008 and a primary completion date of 30 Apr 2012.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT00665470 |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional trial |
| Lead sponsor | National Cancer Institute (NCI) |
| Enrollment | 10 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Metastatic Melanoma and Skin Cancer |
| Drugs | Aldesleukin |
| Start | 30 Apr 2008 |
| Primary completion | 30 Apr 2012 |
| Study completion | 30 Apr 2012 |
| Last update posted | 19 Oct 2015 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Joohee Sul, M.D.
National Cancer Institute (NCI)
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT00665470
Each answer restates registry values shown on this page.
What is NCT00665470?
NCT00665470 is a phase 2 interventional trial sponsored by National Cancer Institute (NCI). It studies Aldesleukin in Metastatic Melanoma and Skin Cancer.
Who leads NCT00665470?
The registry names Joohee Sul, M.D. (principal investigator, National Cancer Institute (NCI)) as the overall official.
Where does NCT00665470 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT00665470 study?
The registered drug and biological interventions are Aldesleukin.
When did NCT00665470 end?
The registry lists a primary completion date of 30 Apr 2012 and a study completion date of 30 Apr 2012. The sponsor last updated the record on 19 Oct 2015.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.